EVALUATING SIBEPRENLIMAB IN PATIENTS WITH IgA NEPHROPATHY: RESULTS FROM AN INTERIM ANALYSIS OF THE CHINA COHORT OF THE PHASE 3 VISIONARY TRIAL

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/12f906a7ce5cea61c0f13238b0f50a62.pdf
EVALUATING SIBEPRENLIMAB IN PATIENTS WITH IgA NEPHROPATHY: RESULTS FROM AN INTERIM ANALYSIS OF THE CHINA COHORT OF THE PHASE 3 VISIONARY TRIAL

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Hong
Zhang
Hong Zhang hongzh@bjmu.edu.cn Peking University First Hospital Renal Division Beijing China *
Adrian Liew draliew2@gmail.com Mount Elizabeth Novena Hospital Nephrology Singapore Singapore -
Muh Geot Wong muh.wong@health.nsw.gov.au Concord Repatriation General Hospital Renal Medicine Concord, Sydney Australia -
Deqiong Xie 1285396756@qq.com Second People’s Hospital of Yibin Nephrology Yibin, Sichuan China -
Caili Wang wangcaili213@163.com The First Affiliated Hospital of Baotou Medical University Nephrology Baotou, Inner Mongolia Province China -
Wanhong Lu lu_wanhong@126.com The First Affiliated Hospital of Xi’an Jiaotong University Nephrology Xian, Shaanxi China -
Guisen Li guisenli@163.com Sichuan Provincial People’s Hospital Renal Chengdu, Sichuan China -
Jing Xia Jing.Xia@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -
Cecile Fajardo Cecile.Fajardo@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -
Jeffrey Hafkin Jeffrey.Hafkin@otsuka-us.com Otsuka Pharmaceutical Development & Commercialization, Inc. Development & Commercialization Princeton, NJ United States -
Jicheng Lv jichenglv@bjmu.edu.cn Peking University First Hospital Renal Division Beijing China -
-
-
-
-